Archemix Presents at Friedman, Billings, Ramsey Investor Conference

CAMBRIDGE, MA - May 26, 2004 - Archemix Corp., the privately-held biopharmaceutical company focused on discovering and developing aptamer-based therapeutics, announced that Dr. Errol De Souza, Archemix's President and Chief Executive Officer, will present at Friedman, Billings, Ramsey's 8^th Annual Growth Investor Conference on Wednesday, June 2^nd, 2004 at 11:20 A.M. The conference will be held at the Millennium Broadway Hotel in New York City.  Dr. De Souza will provide an update on development activities for Archemix's lead compound, ARC183, and additional product portfolio and business developments.

About Aptamers

Aptamers are a new class of molecules that have the potential to revolutionize the diagnosis and treatment of disease. Aptamers are single-stranded nucleic acids that form well-defined three-dimensional shapes, binding target molecules in a manner conceptually similar to antibodies. Like antibodies, aptamers can be used for both therapeutic and diagnostic applications. For these applications, aptamers have a number of desirable characteristics, including high specificity, rapid discovery and development, and production through a reliable and scalable chemical process. As therapeutic agents, aptamers have clinically demonstrated biological efficacy and have excellent, tunable pharmacokinetic properties. The chemical stability and high specificity of aptamers make them ideal diagnostic reagents.

About Archemix Corp.

Archemix Corp. is a privately-held biopharmaceutical company based in Cambridge, Massachusetts. The company's mission is to develop aptamers as a new class of directed therapeutics for the prevention and treatment of chronic and acute disease. Because of their unique properties, aptamers promise to provide a superior alternative to conventional therapeutic approaches and can potentially be used in a wide range of disease areas, including many of those currently addressed by protein-based therapeutics.

Archemix's aptamer expertise is complimented by a dominant patent estate comprised of over 170 issued and 170 pending patents covering the identification and use of all new therapeutic aptamers. In addition to the company's core aptamer technology, Archemix possesses strong expertise in both preclinical and clinical drug development. Further information about Archemix can be found at http://www.archemix.com.

For further information, to attend the presentation or to speak with Dr. Errol De Souza, please contact Davia Temin of Temin and Company at 212 588 8788 or info@teminandco.com.

###